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Purpose/Objective: To assess acute and late toxicities and 
report the frequency and timing of the PSA bounce in 
intermediate-risk prostate cancer patients treated with 
brachytherapy and hypofractionated external beam 
radiotherapy (EBRT) combined with short course androgen 
deprivation therapy (ADT). 
Materials and Methods: Between August 2003 and September 
2007, 51 patients with intermediate-risk prostate cancer 
were enrolled in a dose escalation phase II protocol (BRP-1 
trial). The treatment regimen applied was as followed: 
patients received six months of ADT (three months 
neoadjuvantly and three months concurrently) and 
underwent high-dose-rate (HDR) Ir192 prostate brachytherapy, 
for a prescribed dose of 19.5Gy (three fractions of 6.5Gy 
each); followed one week later, by hypofractionated EBRT at 
a dose of 50Gy in 20 fractions. Patients were assessed one 
month post-treatment, every three to six months for the first 
five years and annually thereafter. APS, testosterone and 
complete blood count were taken on each visit. 
Gastrointestinal (GI), genitourinary (GU) and sexual toxicities 
were assessed according to the RTOG toxicity scoring 
criteria. Patients also completed the Expanded Prostate 
Cancer Index Composite (EPIC) questionnaires for quality of 
life every 6 months. 
Results: Median age was 68.5 years (range 51-83 years). At 
diagnosis, 31.8% of patients had grade 2 or higher for GU 
symptoms according to the RTOG scoring criteria, no one had 
grade 2 GI symptoms and 50% had grade 2 or higher erectile 
dysfunction. Median follow-up was 80 months (range 4.9-132 
months). Rates of grade 2 and higher GU toxicity at 1, 12 and 
60 months were 33.8%, 12.8% and 23.5%, respectively. No 
grade 2 or higher GI toxicities were reported at 1 and 12 
months and a rate of 5.9% was observed at 60 months. Grade 
2 and 3 erectile dysfunction at 1, 12 and 60 months was 
reported in 2.1%, 19.2% and 16.1% and 91.7%, 57.2% and 71% 
of patients respectively. No grade 4 toxicity was reported. 
PSA bounce was observed in 33.3% of patients at a median of 
12 months (range 3-42 months) and the median time to PSA 
normalization was 18 months (range 3-24 months).  
Conclusions: Acute and late GU and GI toxicities were 
acceptable for patients with intermediate-risk prostate 
cancer treated with HDR brachytherapy and hypofractionated 
EBRT combined to short course ADT. Rates of erectile 
dysfunction were probably affected by the use of a short 
course of ADT. PSA bounces are common, and occur up to 42 
months in our cohort. 
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Purpose/Objective: Low dose rate (LDR) brachytherapy is 
accepted as a treatment option for low risk prostate cancer 
producing excellent long term outcomes. The GEC-ESTRO 
guidelines recommend a 100% isodose prescription of 145Gy 
for Iodine-125 implantable seeds. In our practice we 
prescribe to 160Gy to low and intermediate risk cases, as 
increasing dose has been associated with improved outcomes. 
We analysed our implant and post-implant dosimetric 
parameters, relative to the current GEC-ESTRO guidelines.  
Materials and Methods: A single operator cohort of patients 
was selected to control inter-operator variability. Data for 
patients in our Trust is prospectively collected and compiled 
into the ProBrachy European and Royal Berkshire local 
database. Median values were used to assess the 
performance of the cohort. Statistical analysis was performed 
on SPSS v22. 
Results: 
 
 
A total of 95 patients treated with low dose rate 
brachytherapy were identified. Patient characteristics and 
tumour stage are summarised below. Median prostate volume 
implanted was 35.81cc (Range 18.3-83.8cc). Pre-implant 
ultrasound volume assessments showed excellent correlation 
with the implant ultrasound volumes and post implant CT 
(Pearson’s r = 0.926 and 0.93, respectively).  
 
GEC-
ESTRO 
145Gy  160Gy Implant  
(median) 
Post 
Implant  
(median) 
V100 (CTV) ≥95% - - 98% 95% 
D90 (CTV) ≥100%  145Gy 160Gy 186.99 
Gy 
175.5 Gy 
V150 (CTV) ≤50% - - 54% 53% 
D2cc 
Rectum 
≤145Gy 145Gy 160Gy 94.425 
Gy 
72.5 Gy 
D10 Urethra ≤150%  217.5 
Gy 
240 
Gy 
202.83 
Gy 
214.59 Gy 
D30 Urethra ≤130%  188.5 
Gy 
208 
Gy 
193.7Gy  199.27 Gy 
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The range of doses achieved for D2cc Rectum was 52.46 Gy to 
138.27 Gy. 85% of cases achieved D10 Urethra of less than 
217.5Gy, whilst 100% achieved doses of less than 240 Gy. The 
range of doses for D30 Urethra was 172.08 Gy to 222.35 Gy. 
64% of cases received doses greater than 188.5Gy but only 
7.4% of cases received doses greater than 208 Gy. Only 1 
patient required re-catheterisation post procedure. 
Conclusions: The median dosimetric parameters ascribed to 
a 145Gy prescription dose were achieved for all GEC-ESTRO 
described organs at risk, except for the secondary OAR 
parameter of D30 Urethra, using a prescription dose of 160Gy. 
The low rectal doses are noteworthy as is the low rate of re-
catheterisation. This indicates that 160Gy can be safely 
delivered which may in turn improve outcomes. 
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Purpose/Objective: To evaluate two different types of 
stranded seeds in permanent prostate brachytherapy. In the 
first group we used strands with a fixed sequence of seeds 
and spacers, in the second group we could implant strands 
with a variable sequence of seeds and spacers. 
Materials and Methods: From 2007 to 2014 we treated a 
total of 110 low-risk prostate cancer patients with either the 
fixed (IsoCord®, Eckert & Ziegler Bebig, n=74) or the variable 
spacing (Quicklink®, C.R. Bard, n=36) system. Median patient 
age was 65.5 years. All patients were treated by the same 
team of radiation oncologist, urologist and physicist. 
Treatment planning parameters were compared at seed 
implantation and at post-planning 4 weeks later. Toxicities 
and quality of life were evaluated according to CTCAE v4 and 
the EORTC QLQ-C30 and PR-25 questionnaires. To evaluate 
obstructive problems we used the IPSS scoring system. 
Results: Mean prostate volumes were 30.4+11ccm and 
36.9+11ccm (p=0,004). A mean of 52 vs 59 Seeds per patient 
were implanted (p<0,001). At implantation values for D90 
(191.9 vs. 179.9Gy; p<0,001), V100 (99.1 vs. 97.6%; p<0,001), 
V150 (78.5 vs. 70.5%; p<0,001) and V200 (45.1 vs. 37.9%; 
p<0,001) were significantly different. Also D1 for urethra was 
less for the group with variable spacing (225.9 vs. 206.8Gy; 
p<0,001). We observed significant differences at post-
planning in the following DVH parameters: D90 (165.7 vs. 
171.9Gy; p=0,008) and V100 (94.6 vs. 96.0; p<0.001). The 
reduction in D90 values were significantly greater for the 
fixed system (13.7% vs. 4.6%; p<0.001). Homogeneity index 
was significantly different at implantation (20.8 vs. 27.2%) 
but not at post planning (24.8 vs. 25.0%). There were no 
significant changes in rectal V100 and prostate V150 and 
V200. Evaluation of toxicities, IPSS scores and comparison of 
quality of life parameters is still ongoing and will be 
presented at the conference. 
Conclusions: Using the stranded seed system with variable 
spacing we could achieve a reduced dose to the urethra at 
implantation and observed more stable values for prostate 
D90 at post-planning dosimetry.  
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Purpose/Objective: Development of new technologies and 
the applicator MRI studies for the intracavitary radiation 
therapy for cancer of the anal canal, with the aim 
Enhancements treatment results and brachytherapy planning 
and optimization The prognostic relevance of tumor human 
papilloma virus (HPV) status in patients with anal squamous 
cell carcinoma. 
Materials and Methods: in 2012-2014 40 invasive anal 
channel cancer T1-4 N0-1 M0 patients were treated with 
combined chemoradiotherapy. First the patients received 
chemoradiotherapy using cisplatin and capecitabin. EBT was 
performed for minor pelvis and local lymph nodes using a 3D 
technique, since 2010 using IMRT and RapidArc. Total dose 
was 45 Gr. HPV status was revealed using an anal channel 
smear and PCR. At the second phase of radiotherapy - 
brachytherapy applicator used by us made, 25mm diameter, 
with 6 peripheral channels and one central, for the 
MicroSelectron was performed: All training conducted 
dosimetry using MRI scans. Optimal single dose per fraction is 
calculated by a special formula.  
The irradiation was performed three a week, 3 Gy per 
fraction. 5-6 fractions were performed. Total radiation 
dose=18-21Gy. 
Comparison and optimization treatment plans was performed 
with the following parameters: Coverage index, External 
volume index, Relative Dose Homogeneity index, Overdose 
volume index. 
Results: 36 patients out of 40 achieved complete regression 
of the tumor. Annual relapse-free survival rate was 98 
percent of 40 patients, 36 had positive HPV status. Full 
regress of the primary tumor was obtained in 36 (100%) 
patients. Of HPV negative status patients, full response was 
obtained only in 1 patient. 
Conclusions: Applying the new applicator may achieve 
optimal dose distribution and to achieve a greater 
percentage of complete regression. In anal channel patients 
receiving combined chemoradiotherapy, an HPV positive 
status is a favorable prognostic factor of a tumor´s 
radiosensitivity. 
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